A previous study suggested that AMD3100 has the ability to mobilize HSCs into the circulation in lymphoma and multiple myeloma patients for whom HSC mobilization therapy with G-CSF alone failed [27, 28]. This evidence concerns the gene CSF3 and AL amyloidosis.